No Relief For Pfizer As It Shuts Down Additional Tanezumab Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety concerns require Pfizer to scupper two additional studies of its Phase III tanezumab, casting doubt on an entire class of new pain drugs.